Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of “Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned a consensus rating of “Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $13.71.

A number of equities analysts have issued reports on HUMA shares. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Wednesday. Benchmark reissued a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th.

Humacyte Trading Down 2.5 %

Shares of HUMA opened at $1.96 on Friday. Humacyte has a 1-year low of $1.76 and a 1-year high of $9.97. The firm has a market capitalization of $246.68 million, a price-to-earnings ratio of -1.46 and a beta of 1.36. The firm’s 50-day moving average price is $3.61 and its 200-day moving average price is $4.51.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. On average, research analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently made changes to their positions in HUMA. Victory Capital Management Inc. lifted its position in Humacyte by 551.6% in the 3rd quarter. Victory Capital Management Inc. now owns 76,896 shares of the company’s stock valued at $418,000 after acquiring an additional 65,095 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in shares of Humacyte during the third quarter valued at $712,000. Intech Investment Management LLC purchased a new stake in shares of Humacyte during the third quarter valued at $232,000. Charles Schwab Investment Management Inc. increased its holdings in Humacyte by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock worth $3,924,000 after buying an additional 66,946 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Humacyte by 30.5% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 45,575 shares of the company’s stock worth $248,000 after buying an additional 10,656 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.